NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance is stable with improved margins and narrowed losses, but logistical delays and dependence on key partnerships pose risks. The Q&A reveals uncertainties, particularly with AbbVie and logistical challenges, dampening optimism. The reaffirmed guidance and potential positive EBITDA are countered by economic uncertainties and cash flow challenges. Without a clear market cap, the sentiment remains neutral, balancing positive operational efficiencies against logistical and partnership risks.
Key Financial Performance
Revenue $2.9 million, flat year-over-year. Reasons: Consistent performance in contract manufacturing and consumer branded products, along with improved operational efficiencies.
Gross Profit Margin 42.4%, an increase from 39.3% in the third quarter of 2024. Reasons: Decrease in materials and finished products costs, and a decrease in amortization and depreciation.
Cost of Revenues $1.7 million, a decrease of 5.2% year-over-year. Reasons: Decrease in materials and finished products costs, and a decrease in amortization and depreciation, offset by increases in commission and contract fees, and equipment and production expenses.
Gross Profit $1.24 million, slightly higher than $1.16 million in the third quarter of 2024. Reasons: Improved gross profit margin.
Selling, General, and Administrative Expenses $1.96 million, slightly higher than $1.94 million in the third quarter of 2024. Reasons: Increased compensation and benefits, share-based compensation, and professional and consulting fees, offset by a decrease in advertising, marketing, and Amazon fees.
Adjusted EBITDA Loss $354,000, narrowed from $419,000 in Q2 2025 and $500,000 in Q1 2025. Reasons: Sequential growth and improved operational efficiencies.
Net Loss $653,000, compared to $693,000 in the third quarter of 2024. Reasons: Improved gross profit margin and operational efficiencies.
Cash Balance $938,000 as of September 30, 2025. Reasons: Includes $1 million in non-dilutive capital from STADA to support product launches and marketing efforts.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Silly George Lip Gloss: Launched 5 new shades of lip gloss in late September, with strong initial performance.
Kenkoderm Eczema Solutions: Doubling product portfolio by launching new products targeting eczema, expected in the next few months.
MEDAGEL SilverSeal and Burn Pads: Expanded product line with SilverSeal wound and burn kit and moist burn pads, performing well on Amazon.
STADA Partnership Products: Soft launching Glutacin (digestive enzyme for gluten sensitivity) in December, with additional products planned for early 2026.
Health Canada Approval: Received approval to sell SilverSeal in Canada, expanding market reach.
STADA Partnership Expansion: Broadened collaboration with STADA, including $1 million non-dilutive financing for product launches and marketing.
Gross Profit Margin Improvement: Increased gross profit margin to 42.4% in Q3 2025, up from 39.3% in Q3 2024.
Operational Efficiencies: Reduced adjusted EBITDA loss sequentially from $500,000 in Q1 to $354,000 in Q3 2025.
iRhythm Partnership: Supplying hydrogels for Zio ECG heart monitoring system, with first direct orders expected this quarter.
Cintas Partnership: Continued strong relationship with Cintas, with SilverSeal included in wound care kits.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Logistical delays in Consumer Products segment: Unforeseen logistical delays affected the movement of inventory, delaying product launches until late September. This could impact revenue and market momentum if such delays recur.
Dependence on key partnerships: The company's performance in contract manufacturing heavily relies on partnerships with companies like Cintas and iRhythm. Any disruption or termination of these partnerships could adversely affect revenue.
Regulatory and clinical trial risks: The company is awaiting publication of clinical trial data for its hydrogels. Delays or unfavorable results could impact product adoption and market credibility.
Economic uncertainties: The company operates in a competitive and uncertain economic environment, which could affect consumer spending and demand for its products.
Cash flow and profitability challenges: Despite narrowing losses, the company is not yet profitable and has limited cash reserves, which could constrain its ability to invest in growth or weather financial downturns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For the fourth quarter, the company expects revenues to increase sequentially, making Q4 a record quarter. Full-year 2025 revenues are projected to be between $12 million and $12.5 million, with the higher end of the range depending on a strong consumer-branded products holiday season.
Profitability Outlook: The company aims to narrow its adjusted EBITDA loss further in Q4, approaching breakeven.
Consumer Products Segment: New product launches in the Consumer Products segment, including expanded beauty lines and solutions for eczema, are expected to drive growth in the coming months. The company anticipates strong performance during the holiday season.
Partnership with STADA: The partnership with STADA will expand with the soft launch of Glutacin in December 2025 and additional product launches in early 2026. This includes digestive enzyme formulas and skincare solutions targeting scars and stretch marks.
Contract Manufacturing and White Label: The company expects contract manufacturing and white label to remain major drivers of expansion and success moving forward.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you elaborate on the logistical delays and their impact on sales?
A:The delays varied by product, mainly due to customs and new regulations. Existing products were not severely impacted, but new products like lip gloss were delayed, releasing on September 27 instead of late August. The estimated sales impact was $100,000 to $200,000.
Q:What gives you confidence in achieving the revised guidance of 12% to 12.5% for the full year?
A:The company maintained flat performance despite not onboarding new customers in Q3. Growth from existing customers and new customers like iRhythm in Q4 are expected to drive a strong quarter. However, the holiday season's impact on new and existing products remains uncertain.
Q:What is the status of AbbVie and the RESONIC device?
A:The situation is unclear and frustrating. AbbVie indicated they would send a purchase order, but conflicting information suggests they took an impairment charge. The CEO is trying to clarify the situation but remains concerned.
Q:What is the current order book like from the contract manufacturing side?
A:The order book is strong, with growth aligned with the CAGR of medical devices. There is a robust pipeline of potential new customers, with some onboarding in the next two to three quarters.
Q:Do you still have a strong cash position to fulfill orders?
A:Yes, the company has built inventory for both consumer products and raw materials for contract manufacturing. Q4 is expected to strengthen the cash position as inventory is sold and receivables are collected.
Q:Are you still expecting to achieve positive EBITDA by the end of the year?
A:The company believes it is possible, depending on the performance of consumer products in Q4. A strong quarter in contract manufacturing and consumer products could help achieve this goal.
Q:Review of Unclear Management Responses
A:The CEO avoided providing specific details about the current order book for contract manufacturing, citing a preference not to disclose too much information.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amazon approval
Bo conference
Communications sir
Conference Mr
ECG heart
George product
Glutacin enzyme
McGuire Chief
Mr Managing
NEXGEL Financial
Products segment
Reconciliation non
STADA financing
Silly George
Zio
account consumer
afternoon name
analysis iRhythm
attention Consumer
business country
cabinet business
care solution
confidence review
contact journal
country order
customer launch
heart monitor
holiday season
kit
monitoring
product holiday
product launch
wound
NXGL Transcript
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call highlighted a 25% YoY revenue increase, improved gross margins, and a shift from net loss to net income, indicating strong financial performance. Despite the lack of specific strategic guidance, the integration of the acquisition seems to be progressing well. The absence of risk discussion and unclear Q&A responses may slightly temper enthusiasm, but the overall financial health and operational efficiencies suggest a positive sentiment, likely leading to a 2% to 8% stock price increase.
NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call presents a mixed outlook. Financial performance is stable with improved margins and narrowed losses, but logistical delays and dependence on key partnerships pose risks. The Q&A reveals uncertainties, particularly with AbbVie and logistical challenges, dampening optimism. The reaffirmed guidance and potential positive EBITDA are countered by economic uncertainties and cash flow challenges. Without a clear market cap, the sentiment remains neutral, balancing positive operational efficiencies against logistical and partnership risks.
NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call summary and Q&A section reveal strong financial performance, with 121% revenue growth and positive developments in consumer products. Strategic partnerships with major companies like AbbVie suggest future revenue potential despite delays. The company maintains guidance and expects cash flow positivity, indicating financial health. Although there are some uncertainties, like the AbbVie timeline and tariff impacts, the overall sentiment is positive, especially with strong sales from Silly George and new product launches. The positive sentiment outweighs the negatives, suggesting a likely positive stock price movement.
NEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call Transcript
Positive5-15
The earnings call indicates strong financial performance with a 121% revenue increase and improved margins. Despite ongoing challenges like supply chain issues and potential tariff impacts, the company shows resilience with strategic plans to mitigate risks. The Q&A reveals optimism about growth and product launches, though some uncertainties remain. The absence of a shareholder return plan is a minor drawback. Overall, the positive revenue growth, strategic partnerships, and improved financial health suggest a positive stock price movement in the short term.
NXGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
